Rangering i aksjer
#35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
Aksjekurs
$0.82959892
Sist synkronisert: 2023-05-23
Pris IMV pris med markedsverdi på B
Markedsverdi av IMV Inc.(IMV)
Markedsverdi: $4.16M
Per August 2026 har IMV Inc. en markedsverdi på $4.16M. Dette gjør IMV Inc. til det 35289th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for IMV Inc. fra 2012 til 2026
IMV sammenlignet med topp 5 mest populære stocks
| Pris på IMV |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+131,076,102.29%
|
|
|
|
|
$4.490T
|
+107,950,940.04%
|
|
|
|
|
$4.162T
|
+100,074,320.56%
|
|
|
|
|
$3.676T
|
+88,388,142.13%
|
|
|
|
|
$2.833T
|
+68,113,157.05%
|
